Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O1PU
|
|||
| Former ID |
DIB002232
|
|||
| Drug Name |
BAY-39-9624
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Terminated | [1] | |
| Company |
Bayer AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Progesterone receptor (PGR) | Target Info | Agonist | [2] |
| KEGG Pathway | Oocyte meiosis | |||
| Progesterone-mediated oocyte maturation | ||||
| Pathway Interaction Database | Cellular roles of Anthrax toxin | |||
| Reactome | Nuclear signaling by ERBB4 | |||
| Nuclear Receptor transcription pathway | ||||
| WikiPathways | Ovarian Infertility Genes | |||
| Signaling by ERBB4 | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014491) | |||
| REF 2 | Bayer is seeking an exclusive licensee for its end-of-Phase I progestinagonist Bay 39-9624. Thepharmaletter. 29-04-2002. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.